Thermo Fisher Scientific CA19-9/Sialyl Lewisa (GI Tumor Marker) Monoclonal Antibody (SPM588)

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-dependent

-

Immunohistochemistry (PFA fixed) (IHC (PFA))

1-2 µg/mL

-

Immunocytochemistry (ICC/IF)

1-2 µg/mL

-

Flow Cytometry (Flow)

1-2 µg/10^6 cells

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgM, kappa

Class

Monoclonal

Type

Antibody

Clone

SPM588

Immunogen

Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

Protein A/G

Storage buffer

PBS, pH 7.4, with 0.05% BSA

Contains

0.05% sodium azide

Storage conditions

4° C, do not freeze

Shipping conditions

Ambient (domestic); Wet ice (international)

Target Information

Mucin glycoprotein is a Sialyl Lewis A structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis A and/or Lewis B blood group antigens. In normal tissues, sialyl Lewis A antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.